Import Alert Guide
Import Alert 54-14 — Dietary Supplements, GMP
A plain-language guide to FDA Import Alert 54-14, which allows detention without physical examination of dietary supplement products from firms that have not met dietary supplement GMPs. What it covers, why it works differently from a contaminant alert, and what clearing it actually requires.
The Short Version
What Is Import Alert 54-14?
Import Alert 54-14 permits FDA to detain, without physical examination, dietary supplement products from firms that have not met the current good manufacturing practice (cGMP) requirements for dietary supplements. Unlike a contaminant alert, this one is about the manufacturing system: when an FDA inspection finds that a firm's operations don't comply with 21 CFR Part 111, FDA can treat all of that firm's dietary supplement products as adulterated — not because a specific lot tested positive for something, but because the conditions under which they were made don't meet the standard.
- Alert Number
- 54-14
- Products Covered
- Dietary supplement products from Red List firms found not to meet dietary supplement cGMPs
- Charge
- Adulteration — prepared, packed, or held under conditions not meeting cGMP for dietary supplements (Section 402(g)(1))
- Standard
- 21 CFR Part 111 — cGMP for manufacturing, packaging, labeling, and holding dietary supplements
- Basis for Listing
- FDA foreign facility inspection finding systemic GMP deviations
- Official Text
- FDA Import Alert 54-14
The Background
Why 54-14 Works Differently From a Contaminant Alert
In 2007, FDA established Part 111 — the cGMP rule for dietary supplements — which sets the minimum practices for manufacturing, packaging, labeling, and holding a supplement so that it consistently meets specifications for identity, purity, strength, and composition. Any supplement imported into the U.S. is subject to this rule, and FDA inspects foreign supplement manufacturers to check compliance.
When an inspection reveals serious, systemic deviations from Part 111, FDA's finding is not about one contaminated batch — it's that the firm's whole manufacturing system can't be relied on to produce compliant product. On that basis, FDA can place the firm on 54-14 and detain its dietary supplement products without physical examination. Because the concern is the system, the listing typically sweeps in the firm's supplement products broadly rather than a single item.
This is the crucial difference: a Salmonella or pesticide detention can often be answered by testing the specific lot. A GMP detention usually cannot — a clean test on one shipment doesn't demonstrate that the manufacturing system now meets Part 111.
The Evidence
What Clearing a 54-14 Listing Typically Involves
Because the issue is the manufacturing system, the path centers on correcting and documenting GMP compliance — usually confirmed by FDA re-inspection. Testing plays a supporting role, not the lead one.
-
Correct the GMP Deficiencies
The firm addresses the specific Part 111 deviations FDA cited — processes, controls, records, and quality systems — and documents the corrective actions taken. This is regulatory and operational work, typically led by the firm's GMP or regulatory consultant.
-
Document & Support
A removal request to FDA's Division of Import Operations demonstrates the conditions that gave rise to the violation were resolved. Analytical testing of product can support the picture — evidence of identity, purity, strength, and composition — but supports the GMP case rather than replacing it.
-
FDA Gains Confidence
FDA must be satisfied future shipments will comply — often confirmed by re-inspecting the facility. FDA makes the final decision on removal and on the admissibility of any individual entry.
Where testing fits. We coordinate sampling and independent laboratory analysis that can support a GMP corrective-action file — for example, verifying a product's identity, purity, strength, and composition. That evidence strengthens a removal package, but the core of a 54-14 case is GMP remediation and FDA's confidence in the facility, usually work led by your GMP or regulatory consultant. See our laboratory testing coordination guide.
Be Realistic
What This Alert Means in Practice
Honest limitations
- Testing alone usually won't clear it. This is a manufacturing-system alert. A clean result on one shipment does not show the firm's operations now meet Part 111, so lab testing rarely resolves a 54-14 listing by itself.
- It's broad by design. Because the concern is systemic, the listing tends to affect the firm's dietary supplement products generally — not just the item that prompted the inspection finding.
- Removal can require re-inspection. FDA often needs to re-inspect the facility (or otherwise gain confidence in it) before removing a firm, which can make the timeline longer than a contaminant case.
- GMP remediation is the real work. The center of gravity is correcting and documenting the manufacturing system, typically led by a GMP or regulatory consultant — sampling and testing support that effort rather than substitute for it.
Related
Related Alerts & Guides
Drugs — GMP
The drug-side GMP alert — the same manufacturing-system logic applied to drug products.
Read the guide DirectoryOther Supplement Alerts
Dietary supplements face several other alerts — new dietary ingredients, undeclared drug ingredients, and more. Browse the directory.
View directory IndustryDietary Supplement Testing
Category overview: how sampling and testing support supplement importers facing detention.
View industriesSupplements Detained Under 54-14?
Bring Us the Notice — We'll Tell You Honestly Where Testing Helps
Send your FDA Notice of Action and product details. You'll get a straight read on the GMP nature of this alert and where independent testing can genuinely support a corrective-action file — and where it can't — before any commitment.
Urgent detention matters receive priority intake review.
FDA Detention Sampling is an independent private company. We are not affiliated with, endorsed by, or part of the U.S. Food and Drug Administration. This guide is a plain-language summary of Import Alert 54-14; the official alert text published by FDA is authoritative and controls. Sampling, laboratory testing, documentation, and coordination services do not guarantee FDA release, admissibility, acceptance of laboratory results, removal from any import alert, or any specific regulatory outcome. GMP remediation and petitions for removal are regulatory matters typically led by a firm's GMP or regulatory consultant or attorney. FDA makes the final admissibility decision.